General News | BioCryst Pharmaceuticals, Inc.

Skip to main navigation

Home
News & Events
Press Releases Events & Presentations Media Materials
Stock
Stock Quote & Chart Historic Stock Lookup Analyst Coverage
Corporate Governance
Board of Directors Committee Composition Code of Conduct and Ethics Committee Charters Corporate Responsibility
Finance & Filings
Financial Profile SEC Documents Proxy Online Quarterly Results
Investor Resources
Investor FAQ Email Alerts RSS News Feeds

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more about BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Reports Full Year 2025 Financial Results and Provides Business Update

Read more about BioCryst Reports Full Year 2025 Financial Results and Provides Business Update

BioCryst to Present at Upcoming Investor Conference

Read more about BioCryst to Present at Upcoming Investor Conference

BioCryst to Report Fourth Quarter 2025 Financial Results on February 26

Read more about BioCryst to Report Fourth Quarter 2025 Financial Results on February 26

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more about BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema

Read more about BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema

BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range

Read more about BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more about BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference

Read more about BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference

BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years

Read more about BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to

Pagination

Page 1
Next page

Subscribe to General News

Contact Investor Relations

investorrelations@biocryst.com

Investor Tools

Print Page
Printed Materials
Email Alerts
RSS News Feeds
Share Page

© BioCryst Pharmaceuticals, Inc. All Rights Reserved. 2026

Facebook
Twitter
LinkedIn
RSS